---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References"
description: "Reference list for the formulary evidence report on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease. 291 cited documents."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References

<a id="references"></a>

## 5 References

1. [Achenbach and Saft (2021)](https://pubmed.ncbi.nlm.nih.gov/34049236/)
2. [Aetna clinical policy bulletin 1073 (2026)](https://www.aetna.com/cpb/medical/data/1000_1099/1073.html)
3. [Ajitkumar et al. (2025)](https://www.ncbi.nlm.nih.gov/books/NBK559166/)
4. [American Academy of Neurology (2022)](https://www.aan.com/Guidelines/home/GuidelineDetail/558)
5. [American Academy of Neurology movement disorders quality measures](https://www.aan.com/practice/movement-disorders-quality-measures)
6. [Anderson et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6294590/)
7. [Andriessen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11998698/)
8. [Armstrong and Miyasaki (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413759/)
9. [Austedo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208082s018,216354s008lbl.pdf)
10. [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)
11. [Baig et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5027682/)
12. [Bardakjian et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31381522/)
13. [Barer et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10366633/)
14. [Bates et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/27188817/)
15. [Bayen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36055643/)
16. [Bean et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25356969/)
17. [Bell (2026)](https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/)
18. [BioMarin statement, ROCTAVIAN market withdrawal (2026)](https://www.biomarin.com/news/company-statements/biomarin-voluntarily-withdraws-roctavian-from-the-market/)
19. [Blank (2023)](https://www.managedhealthcareexecutive.com/view/first-gene-therapy-for-duchenne-priced-at-3-2-million)
20. [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)
21. [Boersema-Wijma et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10155365/)
22. [Bombard et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2694258/)
23. [Bruzelius et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6579693/)
24. [Burgunder et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3166256/)
25. [Byrne et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5507767/)
26. [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)
27. [Carlozzi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6108175/)
28. [Carlozzi et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28556412/)
29. [Caron et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145682/)
30. [Chen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38142687/)
31. [Christensen et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35618525/)
32. [Claassen et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5331691/)
33. [Claassen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8216765/)
34. [Claassen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8990962/)
35. [ClinicalTrials.gov NCT03628235](https://clinicaltrials.gov/study/NCT03628235)
36. [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)
37. [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)
38. [ClinicalTrials.gov NCT04120493 version 33](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=33)
39. [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)
40. [ClinicalTrials.gov NCT05243017 version 1](https://clinicaltrials.gov/study/NCT05243017?tab=history&a=1)
41. [CMS Cell and Gene Therapy Access Model (2026)](https://www.cms.gov/priorities/innovation/innovation-models/cgt)
42. [Coppen and Roos (2017)](https://pubmed.ncbi.nlm.nih.gov/27988871/)
43. [Crowell et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34350853/)
44. [CTIS 2024-511766-37-00](https://euclinicaltrials.eu/ctis-public/view/2024-511766-37-00)
45. [da Silva van der Laan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39150831/)
46. [DailyMed AUSTEDO prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0)
47. [DailyMed INGREZZA prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417)
48. [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda)
49. [Divino et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23789925/)
50. [Dorey et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5065694/)
51. [Ekkel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37269816/)
52. [El-Sourady et al. (2022)](https://journals.sagepub.com/doi/full/10.1089/jpm.2021.0308)
53. [EMA orphan designation EU/3/17/1957 (2018)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1957)
54. [EMA questions and answers on withdrawal of Nurzigma application (2025)](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_en.pdf)
55. [Erwin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3593716/)
56. [Estevez-Fraga et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33471951/)
57. [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)
58. [Evans et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3786631/)
59. [Evers et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6127509/)
60. [Exuzides et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34730477/)
61. [Exuzides et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8869871/)
62. [Exuzides et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35483335/)
63. [Exuzides et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/35608039/)
64. [Farag et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)
65. [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)
66. [FDA externally controlled trials draft guidance (2023)](https://www.fda.gov/media/164960/download)
67. [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download)
68. [FDA long term follow-up after gene therapy guidance (2020)](https://www.fda.gov/media/113768/download)
69. [FDA orphan drug designation record for AMT-130 (2017)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=525216)
70. [Ferreira et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34842303/)
71. [Fisher and Hayden (2014)](https://pubmed.ncbi.nlm.nih.gov/24151181/)
72. [Frank et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39825184/)
73. [Frisch et al. (2026)](https://www.jmir.org/2026/1/e100284)
74. [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)
75. [Furr Stimming et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37210099/)
76. [Furr Stimming et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089624/)
77. [Furr Stimming et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42446188/)
78. [Fusilli et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30243861/)
79. [Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4524551/)
80. [Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6700281/)
81. [Gokhale and Villa Zapata (2025)](https://pubmed.ncbi.nlm.nih.gov/39973389/)
82. [Grimbergen et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18381643/)
83. [Guzauskas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11332983/)
84. [Hagen (2023)](https://www.managedhealthcareexecutive.com/view/manufacturers-adopt-no-cure-no-pay-pricing-for-hemophilia-gene-therapy)
85. [Hall et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11515112/)
86. [Handsaker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11822645/)
87. [Harding (2026)](https://en.hdbuzz.net/phase-1-results-announced-for-skyhawks-drug-sky-0515/)
88. [Harrison et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36698999/)
89. [Hawkins et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3548262/)
90. [Hawton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6856291/)
91. [Heemskerk and Roos (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269785/)
92. [Helfand (2019)](https://www.fiercepharma.com/pharma/novartis-slaps-2m-plus-pricetag-newly-approved-gene-therapy-zolgensma)
93. [Hensman Moss et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28642124/)
94. [Hergert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33723593/)
95. [Hernandez (2024)](https://en.hdbuzz.net/373/)
96. [Hernandez (2025)](https://en.hdbuzz.net/483-additional-clarity-what-we-know-4-weeks-after-the-uniqure-news/)
97. [Herzog-Krzywoszanska and Krzywoszanski (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474183/)
98. [Ho et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19097181/)
99. [Hubers et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22119091/)
100. [Hubers et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23876196/)
101. [Huntington Study Group (1996)](https://pubmed.ncbi.nlm.nih.gov/8684382/)
102. [Huntington Study Group (2006)](https://pubmed.ncbi.nlm.nih.gov/16476934/)
103. [Huntington Study Group (2016)](https://pubmed.ncbi.nlm.nih.gov/27380342/)
104. [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)
105. [Huntington's Disease Society of America (2020)](https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/)
106. [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/)
107. [Huntington's Disease Society of America genetic testing and your rights](https://hdsa.org/find-help/healthcare-and-future-planning/genetic-testing-and-your-rights/)
108. [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-to-assess-gene-therapy-for-huntingtons-disease/)
109. [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/08/Huntingtons-Disease_Draft-Scope_For-Publication_082026_For-Publication.pdf)
110. [ICER Huntington's disease assessment page (2026)](https://icer.org/assessment/huntingtons-disease-2026/)
111. [ICER model analysis plan (2026)](https://osf.io/download/puega/)
112. [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf)
113. [ICER research protocol (2026)](https://osf.io/download/eyjx6/)
114. [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)
115. [ICER single and short-term therapies adaptations (2022)](https://icer.org/wp-content/uploads/2022/12/ICER_SST_FinalAdaptations_122122.pdf)
116. [Inbar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13379509/)
117. [Ingrezza prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209241Orig1s034lbl.pdf)
118. [Jahanshahi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8332598/)
119. [Johnson et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916295/)
120. [Jones et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5096063/)
121. [Kachian et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30875675/)
122. [Kay et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4955276/)
123. [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download)
124. [Keskin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6849441/)
125. [Keum et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4746370/)
126. [Kim et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11585891/)
127. [Kim et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39373538/)
128. [Knott et al. (2024)](https://www.ispor.org/docs/default-source/intl2024/ispor24tangee72poster139078-pdf.pdf)
129. [Ko et al. (2020)](https://www.mdsabstracts.org/abstract/burden-of-huntingtons-disease-hd-on-loss-of-employment-status-and-its-association-with-disease-stage/)
130. [Langbehn et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15025718/)
131. [Langbehn et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6692683/)
132. [Lee et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9118113/)
133. [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10846961/)
134. [Liu (2025)](https://www.fiercepharma.com/pharma/pfizer-empties-gene-therapy-portfolio-discontinues-hemophilia-treatment-beqvez)
135. [MacLeod et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22642570/)
136. [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/)
137. [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)
138. [Martinez-Horta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26898966/)
139. [Massey et al. (2021)](https://www.mdsabstracts.org/abstract/cost-of-predictive-genetic-testing-for-huntingtons-disease-at-centers-of-excellence-in-the-us/)
140. [McColgan and Tabrizi (2018)](https://pubmed.ncbi.nlm.nih.gov/28817209/)
141. [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/)
142. [McLean et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11015039/)
143. [Medina et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10086981/)
144. [MedlinePlus (2020)](https://medlineplus.gov/genetics/condition/huntington-disease/)
145. [Mestre et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19588393/)
146. [Mestre et al. (2009b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7390161/)
147. [Mestre et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10080408/)
148. [Mestre et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6174516/)
149. [MHRA paediatric investigation plan waiver decision (2026)](https://cms.mhra.gov.uk//system/files/2026-07/mhra-102322-pip01-26.pdf)
150. [Mills et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39101272/)
151. [Miniarikova et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5014463/)
152. [Miniarikova et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5658675/)
153. [Miniarikova et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6079476/)
154. [Minikel (2025)](https://www.cureffi.org/2025/10/08/amt-130/)
155. [Morais et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9455173/)
156. [Morrison et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20880124/)
157. [Mühlbäck et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9887752/)
158. [Myshko (2022)](https://www.managedhealthcareexecutive.com/view/fda-approves-gene-therapy-for-hemophilia-b)
159. [Myshko (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-2-9-million-gene-therapy-for-hemophilia-a)
160. [Myshko (2024)](https://www.managedhealthcareexecutive.com/view/fda-approves-pfizer-s-gene-therapy-for-beqvez-for-hemophilia)
161. [NINDS (2026)](https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease)
162. [Ogilvie et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12021023/)
163. [Ogilvie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316193/)
164. [Ohlmeier et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6905058/)
165. [Oosterloo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307030/)
166. [Oster et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2574833/)
167. [Patel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37285853/)
168. [Patil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11717757/)
169. [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)
170. [Paulsen et al. (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1737562/)
171. [Paulsen et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25453459/)
172. [Pfizer press release, BEQVEZ approval (2024)](https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-beqveztm-fidanacogene-elaparvovec)
173. [Phares et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11609966/)
174. [Pollard et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11576117/)
175. [Poprelka et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40938830/)
176. [Pringsheim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22692795/)
177. [PTC Therapeutics (2026)](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-positive-topline-results-month-24)
178. [Quinn et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7080285/)
179. [Rawlins et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26824438/)
180. [Reilmann (2013)](https://pubmed.ncbi.nlm.nih.gov/23674480/)
181. [Reilmann et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25164527/)
182. [Reilmann et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618238/)
183. [Richardson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7569395/)
184. [Roche (2021)](https://www.roche.com/media/releases/med-cor-2021-03-22b)
185. [Rodrigues and Ferreira (2017b)](https://pubmed.ncbi.nlm.nih.gov/29052699/)
186. [Rodrigues et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5573977/)
187. [Rodrigues et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7611886/)
188. [Rodriguez Santana et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9757103/)
189. [Rodríguez Santana et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11962051/)
190. [Rodríguez-Santana et al. (2021)](https://www.ispor.org/docs/default-source/euro2021/ispor-wpai-patient-poster-final-version-pdf.pdf)
191. [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)
192. [Roiboit and Stout (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12839483/)
193. [Roos (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3022767/)
194. [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)
195. [Sampaio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307057/)
196. [Sathe et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8416308/)
197. [Sawant et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020898/)
198. [Schobel et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729794/)
199. [Sellers et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31466515/)
200. [Shaw et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/35073826/)
201. [Shaw et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9277690/)
202. [Silva-Paredes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6937635/)
203. [Smith et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13522420/)
204. [Snowden (2017)](https://pubmed.ncbi.nlm.nih.gov/28961886/)
205. [Sogorb-Gonzalez et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8093922/)
206. [Sogorb-Gonzalez et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11629698/)
207. [Sokol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9436638/)
208. [Sokol et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10036076/)
209. [Solberg et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5870025/)
210. [Spronck et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6446047/)
211. [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)
212. [Stoker et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34413240/)
213. [Tabrizi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21130037/)
214. [Tabrizi et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23664844/)
215. [Tabrizi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32796930/)
216. [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)
217. [Tarolli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5395679/)
218. [Thomson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232253/)
219. [Thorley et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6132452/)
220. [To et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373050/)
221. [To et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37350423/)
222. [Trundell et al. (2018)](https://medically.roche.com/content/dam/pdmahub/non-restricted/neurology/ehdn-2018/EHDN_2018_HD_cUHDRS_Poster_Trundell_non_restricted.pdf)
223. [Trundell et al. (2019)](https://www.neurology.org/doi/10.1212/WNL.92.15_supplement.P1.8-043)
224. [uniQure expanded access policy (2024)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/uniQure_Expanded-Access-Policy_05June24.pdf)
225. [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)
226. [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)
227. [uniQure Huntington's disease program page](https://www.uniqure.com/programs-pipeline/huntingtons-disease)
228. [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)
229. [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)
230. [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)
231. [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)
232. [uniQure press release, BLA plan after Type B meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons)
233. [uniQure press release, BLA submission (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-submission-biologics-license-application)
234. [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)
235. [uniQure press release, closing of sale to Genezen (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-closing-sale-manufacturing-facility-genezen)
236. [uniQure press release, debt refinancing (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-refinancing-existing-50-million-debt-and)
237. [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)
238. [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)
239. [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated)
240. [uniQure press release, FDA Fast Track designation (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-receives-fda-fast-track-designation-amt-130-gene-therapy)
241. [uniQure press release, FDA RMAT designation (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-receives-fda-regenerative-medicine-advanced-therapy-rmat)
242. [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)
243. [uniQure press release, first patients treated (2020)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-two-patients-treated-phase-iii-clinical)
244. [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)
245. [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)
246. [uniQure press release, full year 2022 results (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2022-financial-results-and-highlights-recent)
247. [uniQure press release, full year 2023 results (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2023-financial-results-and-highlights-recent)
248. [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent)
249. [uniQure press release, IND clearance (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-clearance-investigational-new-drug)
250. [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)
251. [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)
252. [uniQure press release, MHRA pre-submission meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-successful-uk-mhra-pre-submission-meeting-amt)
253. [uniQure press release, pre-BLA meeting feedback (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-0)
254. [uniQure press release, pre-BLA meeting minutes (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-1)
255. [uniQure press release, preclinical publication (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publication-preclinical-data-amt-130)
256. [uniQure press release, preclinical publications (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publications-preclinical-data-amt-130)
257. [uniQure press release, sale of manufacturing facility to Genezen (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-sale-commercial-manufacturing-facility-genezen)
258. [uniQure press release, second quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and)
259. [uniQure press release, second quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2025-financial-results-and)
260. [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and)
261. [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)
262. [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)
263. [uniQure press release, third quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2025-financial-results-and)
264. [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)
265. [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)
266. [uniQure press release, Type A meeting minutes (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2)
267. [uniQure press release, Type A meeting scheduled (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-type-meeting-scheduled-fda)
268. [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)
269. [Vallès et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33827977/)
270. [van der Bent et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9532260/)
271. [van der Zwaan et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35379551/)
272. [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/)
273. [Vonsattel et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/2932539/)
274. [Walker (2007)](https://pubmed.ncbi.nlm.nih.gov/17240289/)
275. [Watkins et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30198875/)
276. [Wesson et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6108173/)
277. [Wexler et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4769413/)
278. [Wheelock et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12654967/)
279. [WHO Proposed INN List 125 (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)
280. [Willock et al. (2021)](https://www.ispor.org/docs/default-source/euro2021/ispor-wpai-caregiver-poster-final-version-pdf.pdf)
281. [Willock et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38108355/)
282. [Wilson et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293766/)
283. [Winder et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30103341/)
284. [Xenazine prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021894s013lbl.pdf)
285. [Yohrling et al. (2019)](https://medically.gene.com/content/dam/pdmahub/restricted/neurology/hsg-2019/HSG-2019-poster-yohrling-prevalence-of-huntington-s-disease-in-the-US.pdf)
286. [Yohrling et al. (2020)](https://www.neurology.org/doi/10.1212/WNL.94.15_supplement.954)
287. [Young et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13071353/)
288. [Youssov et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36084356/)
289. [Youssov et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41014964/)
290. [Yu et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30594932/)
291. [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12799622/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
